Skip to content
thestock.space

Dr. Reddy's Laboratories (DRREDDY) had a P/E of 40.9× on 6 Nov 2026, above the industry P/E of 28.7×. It earns ROCE of 14% and ROE of 7.3%, and sales grew 11% a year over 3 years while net profit fell 1.7%. Its dividend yield is 0.6%, and debt is 0.19× equity. It is a large-cap company with a market cap of ₹1.1 lakh crore, ranked 6th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 14% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,358.40
Day high
₹1,373.00
Day low
₹1,358.40
Prev. close
₹1,366.00
Volume
13.4 L

Health check

3 fair · 3 to check
  • ReturnsIn line

    +13.8% over a year, better than 3 of 7 peers.

  • Price tagPricier

    P/E 40.9 vs industry 28.7.

  • GrowthSlow

    Sales +11.0%, profit −1.7% a year over 3 years.

  • ProfitabilityAverage

    ROCE 14.2% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.19× equity, interest covered 15.7×, Piotroski 4 of 9.

  • Red flags3 to check

    Return on equity is low at 7.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.1L Cr, #6 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹32,984 Cr · profit ₹2,799 Cr
Market cap
₹1.1L Cr
Large cap
P/E
40.9
Industry 28.7
Price to book
2.96
Peers 5.97
Dividend yield
0.58%
ROE
7.3%
Peers 14.7%
ROCE
14.2%
Peers 17.9%
Debt to equity
0.19
Debt ₹7,229 Cr
EPS (TTM)
₹33.59
Face value ₹1
OPM (TTM)
15.9%
Net margin 8.5%
Sales growth
−1.5%
Latest quarter vs a year ago
Profit growth
−35.6%
Latest quarter vs a year ago
Price to sales
3.47
EV/EBITDA 23.0

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 7.3%.
  • Quarterly profit down 35.6% on a year ago.
  • Quarterly sales down 1.5% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a…

Headquarters
Hyderabad
Employees
27,527
Sector
Healthcare
ISIN
INE089A01031
Website
drreddys.com

Price range

52 weeks

₹1,101.00₹1,414.90

Today

₹1,358.40₹1,373.00
Avg volume (3M)
19.5 L
1-year return
plus 13.8%
From 52-week high
minus 3.0%

Analyst consensus

37 analysts
BuyMean target ₹1,358.95 minus 1.0%

The mean target is below today’s price.

Target range, with today’s price

Low ₹1,039.00High ₹1,730.00

Next results expected around 21 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.85%1,26,43346.85.9717.9%14.7%28.2%11.0%12.1%0.29%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
–8,8058,7277,5168,0718,671
–6,4836,7736,8767,2306,863
–2,3231,9546418411,808
–26.4%22.4%8.5%10.4%20.8%
–17481.948014184.2
–90.794.4106126125
247505521558537527
–−66.2122−258234−12.3
–1,8351,5432005531,228
–22.2%22.9%−10.8%21.3%25.6%
–1,4371,210221444925
17.02–14.522.655.3211.10

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+11.0%
Profit CAGR 3Y
−1.7%
EPS CAGR 3Y
−1.7%
ROE
7.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
24,58827,91632,55433,593
–+13.5%+16.6%+3.2%
17,41919,90223,64626,521
7,1698,0158,9077,073
29.2%28.7%27.4%21.1%
155243289386
143171283374
1,2641,4841,7062,061
119585471457
6,0377,1877,6785,482
25.3%22.5%25.4%22.5%
4,5075,5685,6544,285
–+23.6%+1.5%minus 24.2%
54.1766.8067.7851.42

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
83.383.483.483.5
23,01627,97233,25537,623
1,3472,0024,6777,734
7,7398,69511,28412,494
32,18538,75249,29957,935
6,6467,6899,77611,593
9961,4462,4841,541
5365261,5201,637
6,1808,1475,7918,781
17,82820,94529,72834,383
32,18538,75249,29957,935

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5,8884,5434,6435,676
−4,137−4,028−5,808−6,551
−2,686−3761,891829
−936139726−46.8
−1,887−2,744−3,440−3,843
4,0011,8001,2031,833
−498−665−666−666

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 53.8% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you